Publications by authors named "Eric Bercaw"

Claim this Profile
B
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Zahra Mahmoudjafari, Jia Li, Eric Bercaw, Hélène Parisé, Katalin Bognar

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis.
Jesse Fishman, Yestle Kim, Michael R Charlton, Zachary J Smith, Tom O'Connell, Eric M Bercaw

Adv Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Jesse Fishman, Yestle Kim, Hélène Parisé, Eric Bercaw, Zachary Smith

J Med Econ· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu

Pharmacoeconomics· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests.
Jesse Fishman, Tom O'Connell, Christina M Parrinello, Jonathan J Woolley, Eric Bercaw

J Health Econ Outcomes Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis